Intra-Cellular Ther (ITCI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -111,095 | -86,837 | -44,053 | -256,256 | -212,230 |
| Depreciation Amortization | -5,469 | -3,413 | -1,603 | 1,103 | -204 |
| Accounts receivable | -27,481 | -20,775 | -6,356 | -55,033 | -41,382 |
| Accounts payable and accrued liabilities | 218 | -2,662 | -1,954 | 1,704 | 5,528 |
| Other Working Capital | -43,619 | -30,328 | -24,871 | -58,136 | -50,481 |
| Other Operating Activity | 65,308 | 47,147 | 18,771 | 96,432 | 67,776 |
| Operating Cash Flow | $-122,138 | $-96,868 | $-60,066 | $-270,186 | $-230,993 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -268 | N/A | N/A | -778 | -806 |
| Purchase Of Investment | -310,805 | -174,411 | -108,457 | -759,209 | -643,707 |
| Sale Of Investment | 369,192 | 252,697 | 91,995 | 631,614 | 465,877 |
| Investing Cash Flow | $58,119 | $78,286 | $-16,462 | $-128,373 | $-178,636 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 14,806 | 12,225 | 3,640 | 455,159 | 452,972 |
| Financing Cash Flow | $14,806 | $12,225 | $3,640 | $455,159 | $452,972 |
| Beginning Cash Position | 150,365 | 150,365 | 150,365 | 93,765 | 93,765 |
| End Cash Position | 101,152 | 144,008 | 77,477 | 150,365 | 137,108 |
| Net Cash Flow | $-49,213 | $-6,357 | $-72,888 | $56,600 | $43,343 |
| Free Cash Flow | |||||
| Operating Cash Flow | -122,138 | -96,868 | -60,066 | -270,186 | -230,993 |
| Capital Expenditure | -268 | 0 | N/A | -778 | -806 |
| Free Cash Flow | -122,406 | -96,868 | -60,066 | -270,964 | -231,799 |